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The ErbB2 receptor (also known as
HER2/neu) is a member of the epidermal
growth factor receptor family that, in
addition to ErbB2, includes the ErbB1 (or
Epidermal Growth Factor Receptor),
ErbB3, and ErbB4 receptors. The bind-
ing of the EGF family of ligands to ErbB
receptors induces receptor activation by
both receptor homodimerization and het-
erodimerization, thus generating a com-
plex array of combinatorial signals. This
horizontal network of interactions is cru-
cial to the ErbB signaling pathway, since
ErbB3 is devoid of intrinsic kinase activi-
ty and ErbB2 is a ligand-less receptor.
Therefore, in isolation neither ErbB3 nor
ErbB2 have the capacity to initiate down-
stream signaling. An exception to the
rule is that ErbB2 can spontaneously
form active ligand-less homodimers in
cells overexpressing ErbB2 (for review
see Yarden and Sliwkowski, 2001).
The normal function of this family of
receptors and their ligands is to mediate
cell-cell interactions in organogenesis
and adulthood. Deregulation of the tight-
ly regulated ErB receptor signaling path-
ways leads frequently to malignant trans-
formation. In a variety of tumor types,
ErbB pathways become activated by
several mechanisms including overpro-
duction of ligands, overexpression of
receptors, or constitutive activation of
A new anti-ErbB2 strategy in the treatment of cancer:
Prevention of ligand-dependent ErbB2 receptor heterodimerization
Preventing ligand-dependent ErbB2 receptor heterodimers by an anti-ErbB2 monoclonal antibody shuts down receptor
signaling and has potent antitumor activity even in tumors that express low levels of ErbB2, a finding that could result in a
larger number of patients benefiting from anti-ErbB2 therapies.
Figure 1. Prevention of ErbB2 receptor signaling by the monoclonal antibody 2C4
A: In unperturbed conditions, ErbB2 is activated by ligand-induced heterodimerization with other ErbB receptors, which in turn results in activation
of the MAPK and PI3kinase/Akt pathways. B: The monoclonal antibody 2C4 binds to the extracellular domain of ErbB2 and sterically blocks the
association of ErbB2 with other ErbB family members. As a result, it prevents downstream receptor signaling.
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receptors. In particular, the ErbB2 recep-
tor is amplified in 30% of breast cancers
and its overexpression correlates with a
worse prognosis (Slamon et al., 1987).
The critical role of ErbB receptors in the
development of solid tumors has made
these receptors attractive targets for
pharmacological intervention. Strategies
being developed include (1) monoclonal
antibodies directed at the easily accessi-
ble extracellular domain of these recep-
tors and (2) small molecules that com-
pete with ATP for binding to the ATP site
in the receptor tyrosine kinase domain
and that abrogate the receptor’s catalytic
activity, its receptor autophosphoryla-
tion, and its engagement with signal
transducers.
The concept of targeting ErbB recep-
tors as an anticancer strategy has
already been validated in the clinic. The
first agent of this new class of com-
pounds approved for clinical use has
been Herceptin®, a humanized mono-
clonal antibody directed at the ErbB2
receptor that has antitumor activity
(Vogel et al., 2002) and that results in
improved survival in patients with
advanced breast cancer that have ErbB2
amplification (Slamon et al., 2001). Her-
ceptin exerts its antitumor activity by sev-
eral mechanisms including receptor
downmodulation, prevention of cleavage
of the receptor’s extracellular domain
(which leads to receptor constitutive acti-
vation), and by recruiting host’s immune
effector cells (Baselga et al., 2001).
However, even in ErbB2-overexpressing
breast tumors, Herceptin has antitumor
activity in only up to one-third of patients,
and it does not have any activity against
tumors expressing lower levels of ErbB2.
Although it is likely that other coexisting
mechanisms may be responsible for the
malignant growth of these tumors (and
this could potentially explain their lack of
response to Herceptin), it is also possible
that Herceptin may not be interfering
successfully with ErbB2 signaling. In
fact, Herceptin is not capable of inhibiting
signaling by ligand-induced ErbB2-con-
taining heterodimers, a clearly important
mechanism of receptor activation.
In this issue of Cancer Cell, Agus,
Sliwkowski, and colleagues (Agus et al.,
2002) report that the anti-erbB2 mono-
clonal antibody 2C4 that binds to a differ-
ent epitope than Herceptin in the recep-
tor’s extracellular domain sterically blocks
the association of ErbB2 with other ErbB
family members. As a consequence, it
prevents ligand-dependent ErbB2 signal-
ing in both low- and high-ErbB2-express-
ing tumor cell lines (Figure 1).The antitu-
mor effects of 2C4 both in vitro and in
vivo are remarkable in a variety of breast
and prostate carcinoma cell lines. The
findings in prostate carcinoma cells lines
are particularly interesting, since there
is growing evidence that ErbB2 activa-
tion by ErbB ligands produced in the
stroma of the tumor may play an impor-
tant role in the progression to androgen-
independent prostate tumors (Feldman
and Feldman, 2001). In addition, 2C4
may be active and should be tested in
other ErbB2-expressing tumor types
such as non-small cell lung cancer,
ovarian carcinoma, and bladder cancer,
to name a few.
These findings are the basis for the
ongoing clinical development of this
compound and 2C4 in an initial (phase I)
study has been found to be safe without
dose-limiting toxicities, and efficacy
(phase II) studies are to be begin soon
in a variety of tumor types. As 2C4 is
being studied in the clinic, several ques-
tions arise. First, it will be important to
identify the patients that may benefit
from 2C4 therapy. Will it be required to
demonstrate the expression of ErbB2
or, even more complicated, the pres-
ence of ligand-induced heterodimers in
the cell surface of these tumors? Will it
be possible to use as pharmacodynam-
ic markers of sensitivity to 2C4 the inhi-
bition of some of the key downstream
receptors’ signal transduction pathways
such as MAPK and Akt? Another impor-
tant issue is whether this antibody, devoid
of any immune-mediated antitumor activi-
ty, will offer any additional advantage to
the orally bioavailable small-molecular-
weight ErbB tyrosine kinase inhibitors that
are in late stages of clinical development.
These tyrosine kinase inhibitors can
induce inactive ErbB1 homodimers and
ErB2-containing heterodimers (Arteaga
et al., 1997) and impair ligand-induced
ErbB2 transactivation. Further, because
of the great homology in the kinase
domain between the different ErbB
receptors, some ATP-competitive small
molecules can block the catalytic activity
of more than one receptor (reviewed in
Fry, 2000), a property not shared by 2C4,
Herceptin, or anti-ErbB1 receptors due
to their specificity of binding to a particu-
lar receptor extracellular domain epitope.
Whether this capacity to prevent kinase
activation of more that one receptor will
result in greater antitumor activity or, on
the other hand, in unacceptable toxicity,
is unknown at this time.
In summary, preventing receptor het-
erodimerization appears to be a promis-
ing novel approach to the therapy of
ErbB2-expressing tumors, and the mono-
clonal antibody 2C4 does this successful-
ly. This observation suggests that in the
emerging area of anti-ErbB2 therapies,
there is hope beyond Herceptin. There
are many ways to attack a receptor’s
function and 2C4—and the small ErbB
tyrosine kinase inhibitors—are valid new
additions to our anti-erbB receptors arm-
amentarium. The availability of agents
with nonoverlapping mechanisms of
action directed at the same receptor
implies that selection of therapy may not
be any longer based solely on expres-
sion of the target but rather on functional
assays that predict the best antireceptor
strategy for a given tumor. It may also
allow for sequential anti-ErbB2 thera-
pies, since acquired resistance to one of
these agents may not result in resistance
to another agent in a similar fashion as it
occurs with hormonal agents in the ther-
apy of breast cancer. Finally, it also pro-
vides an opportunity to explore combin-
ing these agents in a full-scale anti-
ErbB2 war by inducing receptor down-
regulation and an antireceptor immune
response (Herceptin) by isolating ErbB2
from its transactivating ErbB partners
(2C4) and by eliminating any remaining
receptor catalytic activity (small tyrosine
kinase inhibitors).
Jose Baselga
Vall dHebron University Hospital and
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Imbalanced rates of apoptosis have
been proposed to create a platform that
is necessary and sufficient for tumor for-
mation (Green and Evan, 2002). The
host environment can influence cancer
outgrowth by altering tumor gene
expression, resulting in tumor prolifera-
tion and suppression of the endogenous
apoptotic program. Fas and Fas ligand
(FasL) are an interacting, extracellular
proapoptotic receptor/ligand pair (re-
viewed in Nagata, 1999). Trimerization of
membrane bound Fas with FasL causes
recruitment of the FADD adaptor protein
and procaspase-8, the key initiator cas-
pase in the death receptor pathway.
Procaspase-8 is activated by induced
proximity and further activates down-
stream caspases and initiates cleavage
of critical apoptotic substrates. Active
caspase-8 also engages the intrinsic
mitochondrial pathway of apoptosis
through the cleavage of Bid, which
translocates to the mitochondria and
promotes release of cytochrome c.
The role of Fas-induced apoptosis in
the maintenance of immune homeostasis
is well established (Nagata, 1999). More
recently, Fas-induced apoptosis has been
implicated in the control of tumor progres-
sion and chemotherapeutic drug-induced
death. Functional Fas is highly expressed
on a variety of nonmalignant tissues,
while Fas loss-of-function commonly
accompanies the malignant phenotype.
Multiple molecular mechanisms underlie
Fas loss-of-function in cancer including
downregulation of transmembrane Fas
by promoter methylation (reviewed in
Owen-Schaub et al., 2000), transcrip-
tional repression (Ivanov et al., 2001),
histone acetylation (Maecker et al.,
2000), and alternative mRNA splicing to
produce soluble Fas protein lacking a
transmembrane anchor (reviewed in
Owen-Schaub et al., 2000). Overexpres-
sion of the degenerate caspase homolog
c-FLIP (Bullani et al., 2001) and inacti-
vating Fas mutations (reviewed in Owen-
Schaub et al., 2000) have also been
shown to contribute to Fas loss-of-func-
tion in nonhematopoietic cancers. In sev-
eral cancer types, Fas loss-of-function
has been shown to track with an aggres-
sive disease presentation and de-
creased patient survival. In experimental
animal models (reviewed in Owen-
Schaub et al., 2000), disruption of Fas
has been shown to result in enhanced
tumor development while Fas restoration
has been shown to delay primary tumor
outgrowth. The acquired ability to spread
and metastasize represents the most
intractable feature of cancer. Recent
studies have implicated Fas and FasL
interactions in the control of distant
metastases (Owen-Schaub et al., 1998)
as well as in the development of
chemotherapeutic resistance in some
cell types (reviewed in Johnstone et al.,
2002). These observations suggest that
Fas is a frequent target for inactivation
during oncogenesis and that Fas-
induced apoptosis plays a crucial role in
the biology and response of malignant
disease.
Both transmembrane and cleaved
FasL can induce Fas clustering and initi-
ate apoptotic cell death (Nagata, 1999).
Although some nonhematopoietic tissues
(retinal pigment epithelial cells and lung
epithelial cells, for example) display FasL,
expression is most prominent in bone
marrow-derived immune cells including
activated lymphocytes, neutrophils, nat-
ural killer (NK) cells, and macrophages.
Conceivably, FasL+ immune effectors
could inhibit Fas+ tumor survival by direct
Fas function and tumor progression: Use it and lose it
Recent studies have provided evidence that Fas and FasL interactions are important in the control of malignant disease
and that changes in the level of Fas expression can determine immune escape and therapeutic responses.
Figure 1. Model for Fas loss-of-function in
tumor progression
This model is supported by the findings of
Maecker et al. (2002) that Fas is important for
NK cell-mediated immune surveillance and
chemosensitivity.
